In this episode, Anthony and Bernie are joined by a panel of experts to discuss (and debate) everyone's favorite (or most feared) hematology topic - hemophagocytic lymphohistiocytosis (HLH)!

Joining us on this spicy episode are:

- Justin Kaner, MD

- Madeleine Ochs, PharmD, BCOP

- Catherine Johnson, PharmD, BCOP

How should we manage these patients? H-Scores or HLH2004 criteria? What is the role for ruxolitinib? Emapalumab? CXCL9 levels? Grab your favorite drink and have a listen!

Anthony and Bernie are joined by special guest Jonathan Gluck, award-winning journalist and author of "An Exercise in Uncertainty: A Memoir of Illness and Hope" for a powerful conversation about living through uncertainty.

Drawing on his decades-long journey with multiple myeloma, Jon reflects on the emotional, clinical, and existential uncertainties that shape living with cancer. The discussion moves beyond the patient experience to explore how uncertainty permeates everyday life, as well as oncology practice, including waiting for new therapies to become available, navigating logistical (and insurance) barriers, and interpreting evolving clinical trial data where the answers are not always clear.

Jon is graciously donating a portion of the proceeds of the book to multiple myeloma research, so everyone who picks up a copy is donating to a good cause!

https://www.penguinrandomhouse.com/books/760582/an-exercise-in-uncertainty-by-jonathan-gluck/

In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts should change practice? Listen to find out.

Some of the abstracts discussed:

• PARADIGM: https://meetings-api.hematology.org/api/abstract/vmpreview/296881
• KMT2A Outcomes (MARROW Consortium and Othman, et al.): https://meetings-api.hematology.org/api/abstract/vmpreview/302582 and https://meetings-api.hematology.org/api/abstract/vmpreview/297333
• CLIA +/- Ven: https://meetings-api.hematology.org/api/abstract/vmpreview/302047
• FLT3i studies (and MRD): https://meetings-api.hematology.org/api/abstract/vmpreview/295719 and https://meetings-api.hematology.org/api/abstract/vmpreview/302699 and https://meetings-api.hematology.org/api/abstract/vmpreview/291322
• ALL GIMEMA Trial (blin + ponatinib): https://meetings-api.hematology.org/api/abstract/vmpreview/296532
• Menin inhibitor data

Anthony and Bernie discuss the PARADIGM study that was presented at the plenary session of ASH 2025 and whether results should change our practice. 

https://meetings-api.hematology.org/api/abstract/vmpreview/296881

In this study, Bernie and Anthony are joined by the majestic myeloma man Manni Mohyuddin to discuss key ASH abstracts in myeloma, including the results of the MajesTEC-3 study!

In this episode, Anthony and Bernie discuss the important role of community hematology. We discuss innovative research models, partnerships between community and academic practices, and ways to improve care for hematology patients who live near and far!

In this episode, Bernie and Anthony review the optimal management of febrile neutropenia! We talk about some historical data, optimal patient workup, proper selection of antibiotics, and a discussion of newer data regarding early antibiotic de-escalation in FN.

We're back after a summer break! In this episode, Anthony and Bernie review the optimal approach to antimicrobial prophylaxis in hematology patients. How do you best choose prophylaxis for your patients? Where are we using data and where are we just making things up? Does everyone need antifungal, antibacterial, antiviral, and anti-PJP prophylaxis? We will demystify prophylaxis guidelines for you!

In this episode, Bernie and Anthony talk about some BIG changes in cytarabine dosing in AML consolidation after a recent practice changing article. Will this change your practice?

Hunault, et al. NEJM. 2025.

https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400326

In this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!